Linked pyridinyl-thiadiazoles: Design and synthesis as potential candidate for treatment of XDR and MDR tuberculosis.
Multi-drug resistant (MDR) and extremely drug resistant (XDR) Mycobacterium tuberculosis strains have turned tuberculosis (TB) as "on the verge of eradication" to "most life threatening" disease. Furthermore, synergy with HIV and other immunosuppressive disease have strengthened its prevalence. This research reports small molecule anti-infectives which are specifically potent against several strains and isolates of TB. The hit compound 7f has also proved to be active against almost 25 clinical isolates comparable to marketed anti-TB agents.
Department of Pharmaceutical Chemistry, Adarsh College of Pharmacy, Bhavani Nagar, Kundal Road, Vita 443201, Maharashtra, India. Electronic address: nsmahajanns@gmail.com.
Niranjan S
NS
Mahajan
School of Pharmacy, Swami Ramanand Teerth Marathwada University, Vishnupuri, Nanded 431 606, Maharashtra, India.
S C
SC
Dhawale
D000995:Antitubercular Agents / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D006801:Humans; D008826:Microbial Sensitivity Tests; D015394:Molecular Structure; D009169:Mycobacterium tuberculosis / Q000187:drug effects*; D011725:Pyridines / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology*; D013329:Structure-Activity Relationship; D013830:Thiadiazoles / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology*; D018088:Tuberculosis, Multidrug-Resistant / Q000188:drug therapy*
D000995:Antitubercular Agents; D011725:Pyridines; D013830:Thiadiazoles
Clinical isolates; MDR-TB; Mycobacterium tuberculosis; Pyridine; Thiadiazole